Back

VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

iwNHL 2015 | Ibrutinib, Bruton’s tyrosine kinase inhibitor, for non-Hodgkin lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Thomas J. Kipps, MD, PhD, of the University of California, San Diego, San Diego, CA, discusses the currently available data on the safety and efficacy of ibrutinib, a first-in-class, oral, irreversible inhibitor of Bruton’s tyrosine kinase, for the treatment of patients with non-Hodgkin lymphoma, including mantle cell lymphoma, Waldenström’s macroglobulinemia and diffuse large B-cell lymphoma.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter